Please login to the form below
Healthcare terms - O
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W |
Healthcare Glossary
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W |
Healthcare terms - O
- Objectives
- Off-label use
- Offensive marketing
- Oligopsony
- Omnibus survey
- One to one marketing (1:1 marketing)
- One-on-one interview
- Online learning
- Open ended question
- Open observation
- Open-label trial
- Opinion leader
- Opportunities to hear (OTH)
- Opportunities to see (OTS)
- Opportunity cost
- Optimising
- Order bias
- Organic growth/development
- Orphan drugs
- Outlier
- Output evaluation
- Outsourcing
- Over the counter (OTC)
COVID-19 Updates and Daily News
Featured jobs
-
CEO Pricing & Market Access, UK
-
Six figure salary
-
Senior Account Manager
-
Competitive salary offered
-
Omnichannel Strategy Consultant
-
Competitive Salary
-
CEO, Head of Health, UK
-
Six figure salary
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Valneva COVID-19 vaccine more effective than AZ
- Biosimilars boosted by FDA's landmark ruling for Boehringer’s Cyltezo
- Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
- Biogen's ALS drug tofersen misses phase 3 endpoint
- Merck receives first breast cancer approval in Europe for Keytruda
- Benefits of COVID-19 vaccine in younger children outweigh risks, says FDA
- Call for industry innovators to join working group
- Pfizer-BioNTech booster offers 95.6% efficacy against COVID-19
- US COVID-19 booster programme expanded
- The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
- Curb your conservatism: can pharma ditch its cautious approach to creativity in comms?
- Breaking the silence: It’s time to talk about the menopause
- Valneva COVID-19 vaccine more effective than AZ
- Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes
